Modified oHSV with HRG for Cancer Therapy
Summary
The USPTO published patent application US20260097088A1 for a modified oncolytic herpes simplex virus (oHSV) engineered with an expression cassette encoding histidine-rich glycoprotein (HRG) for use in cancer therapy. The invention, filed on August 17, 2023 (Application No. 19113359), leverages virotherapy to selectively target and lyse cancer cells while sparing normal cells. The inventors are Chun-Yu Chen, Pin-Yi Wang, and Timothy P. Cripe.
What changed
The USPTO published patent application US20260097088A1 covering a modified oncolytic herpes simplex virus comprising an expression cassette encoding histidine-rich glycoprotein (HRG) and its use in cancer therapy. The invention falls within CPC classifications A61K 35/763, A61K 38/1741, A61P 35/00, C12N 7/00, and related C12N 2710 series codes, indicating therapeutic applications in oncology.
Pharmaceutical companies developing cancer therapeutics and biotechnology firms engaged in oncolytic virus research should monitor this pending application. If granted, the HRG-encoding oHSV claims may affect freedom-to-operate assessments and competitive landscape analysis in the cancer virotherapy space.
What to do next
- Monitor for patent examination updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MACROPHAGE POLARIZING ONCOLYTIC HERPES SIMPLEX VIRUS FOR CANCER THERAPY
Application US20260097088A1 Kind: A1 Apr 09, 2026
Inventors
Chun-Yu Chen, Pin-Yi Wang, Timothy P. Cripe
Abstract
This disclosure relates to a modified oncolytic herpes simplex virus (oHSV) comprising an expression cassette encoding a histidine-rich glycoprotein (HRG), and uses thereof. One promising avenue for the treatment of cancer is oncolytic virotherapy, e.g., oncolytic Herpes Simplex Virus (oHSV) which utilizes genetically modified viruses to selectively target and lyse cancer cells while sparing the normal cells. Oncolytic virotherapy is a safe and effective immunotherapeutic platform for different types of cancers.
CPC Classifications
A61K 35/763 A61K 38/1741 A61P 35/00 C12N 7/00 C12N 2710/16622 C12N 2710/16634 C12N 2710/16671
Filing Date
2023-08-17
Application No.
19113359
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.